Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114 (pmc.ncbi.nlm.nih.gov)

· 17d ago · Report · Spotlight this ·

0xBASE INTEL BRIEF

Phase 1 trial shows favorable safety profile.
Neutralizes Zaire Ebola strain.
Derived from survivor antibodies.
Supports single-dose regimen.

"This article details a clinical study on mAb114, a monoclonal antibody candidate for Ebola virus disease. It covers safety, tolerability, pharmacokinetics, and immunogenicity data from Phase 1 trials, supporting its potential as a therapeutic. The findings are crucial for the medical countermeasure pipeline."

#mAb114 monoclonal antibody #Ebola therapeutic pipeline #Phase 1 clinical trial

Read article on pmc.ncbi.nlm.nih.gov → | More from pmc.ncbi.nlm.nih.gov

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114 (pmc.ncbi.nlm.nih.gov)

Discussion Matrix